Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 1
2007 3
2008 3
2009 6
2010 8
2011 6
2012 4
2013 3
2014 6
2015 8
2016 13
2017 10
2018 6
2019 10
2020 9
2021 6
2022 8
2023 8
2024 7

Text availability

Article attribute

Article type

Publication date

Search Results

101 results

Results by year

Filters applied: . Clear all
Page 1
Concerns about the ALIFE2 trial.
Yanagisawa R, Fujiwara SI, Sato T. Yanagisawa R, et al. Lancet. 2024 Jan 20;403(10423):246-247. doi: 10.1016/S0140-6736(23)02339-5. Lancet. 2024. PMID: 38245242 No abstract available.
The REVAMP trial: key questions remain.
Sato T, Yanagisawa R. Sato T, et al. Among authors: yanagisawa r. Lancet. 2024 Jan 6;403(10421):28-29. doi: 10.1016/S0140-6736(23)01919-0. Lancet. 2024. PMID: 38184334 No abstract available.
Unrelated female-to-male bone marrow transplantation would be preferred over cord blood transplantation in male patients.
Tamaki M, Akahoshi Y, Okada Y, Uchida N, Tanaka M, Doki N, Sawa M, Maruyama Y, Ueda Y, Miyakoshi S, Katayama Y, Kawakita T, Kimura T, Onizuka M, Fukuda T, Atsuta Y, Yanagisawa R, Yakushijin K, Kanda J, Nakasone H. Tamaki M, et al. Among authors: yanagisawa r. Cytotherapy. 2023 Nov;25(11):1220-1228. doi: 10.1016/j.jcyt.2023.06.002. Epub 2023 Jun 20. Cytotherapy. 2023. PMID: 37341665
Analysis of risk factors for fatal renal complications after allogeneic hematopoietic cell transplantation.
Yanagisawa R, Koyama H, Yakushijin K, Uchida N, Jinguji A, Takeda W, Nishida T, Tanaka M, Eto T, Ohigashi H, Ikegame K, Matsuoka KI, Katayama Y, Kanda Y, Sawa M, Kawakita T, Onizuka M, Fukuda T, Atsuta Y, Shinohara A, Nakasone H. Yanagisawa R, et al. Bone Marrow Transplant. 2024 Mar;59(3):325-333. doi: 10.1038/s41409-023-02172-4. Epub 2023 Dec 16. Bone Marrow Transplant. 2024. PMID: 38104219
Comparative Analysis of Allogeneic Bone Marrow Transplantation Outcomes Between Japanese and Non-Japanese Populations.
Yanagisawa R, Shindo M, Shinohara A, Kuwatsuka Y, Nakase K, Kimura F, Shingai N, Nishida T, Fukuda T, Sakurai M, Kurokawa M, Koike T, Ota S, Takada S, Onizuka M, Uchida N, Tanaka M, Noguchi M, Maruyama Y, Hagihara M, Ichinohe T, Atsuta Y, Kanda J, Nakasone H, Toubai T. Yanagisawa R, et al. Transplant Proc. 2024 Mar;56(2):416-421. doi: 10.1016/j.transproceed.2024.01.049. Epub 2024 Feb 9. Transplant Proc. 2024. PMID: 38336483
Basophil activation test for allergic and febrile non-haemolytic transfusion reactions among paediatric patients with haematological or oncological disease.
Usami Y, Yanagisawa R, Kanai R, Ide Y, Konno S, Iwama M, Futatsugi A, Takeshita T, Furui Y, Komori K, Kurata T, Saito S, Tanaka M, Nakazawa Y, Sakashita K, Tozuka M. Usami Y, et al. Among authors: yanagisawa r. Vox Sang. 2023 Jan;118(1):41-48. doi: 10.1111/vox.13365. Epub 2022 Oct 12. Vox Sang. 2023. PMID: 36224113
Dendritic Cell-Based Cancer Immunotherapy Targeting Wilms’ Tumor 1 for Pediatric Cancer.
Shimodaira S, Hirabayashi K, Yanagisawa R, Higuchi Y, Sano K, Koizumi T. Shimodaira S, et al. Among authors: yanagisawa r. In: van den Heuvel-Eibrink MM, editor. Wilms Tumor [Internet]. Brisbane (AU): Codon Publications; 2016 Mar. Chapter 8. In: van den Heuvel-Eibrink MM, editor. Wilms Tumor [Internet]. Brisbane (AU): Codon Publications; 2016 Mar. Chapter 8. PMID: 27512771 Free Books & Documents. Review.
101 results